Neoadjuvant Chemoimmunotherapy in Stage IIIA- N2IIIB Non-small Cell Lung Cancer

N/ANot Yet RecruitingNCT06394427

West China Hospital250 enrolled

Overview

to explore the impact of preoperative neoadjuvant immunotherapy on perioperative outcomes and long-term prognosis of locally advanced NSCLC in the real world

Study Type

OBSERVATIONAL

Enrollment

250

Conditions

Non-small Cell Lung Cancer Stage ⅢA Non-small Cell Lung Cancer Stage IIIB

Interventions

cycles of neoadjuvant therapy and duration of waiting for surgeryOTHER

We intended to explore the cycles of neoadjuvant therapy and duration of waiting for surgery on the perioperative outcomes and long-term prognosis of locally advanced NSCLC in the real world

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Confirmed as primary lung cancer through cytology or histological examination; * ECOG score of 0 or 1; ③ 18 years old or above; * Received imaging examination, with a preliminary clinical staging of stage III; * Received genetic testing and tested negative for EGFR mutations, ALK or ROS-1 fusion; ⑥ Accepting preoperative neoadjuvant immunotherapy combined with chemotherapy; ⑦ Receive surgical treatment after completion of neoadjuvant therapy; ⑧ The postoperative specimens were sent to the pathology department of our hospital for pathological testing, and a complete pathological report is available. Exclusion Criteria: * Patients with combined small cell lung cancer; ② Patients with severe liver/kidney dysfunction, cardiovascular disease, or systemic immune disorders; * Accept other neoadjuvant treatments; ④ Patients participating in any clinical trial.

Outcomes

Primary Outcomes

major pathological remission

proportion of patients with no more than 10% residual viable tumor cells; patients who showed no viable tumor in the lung primary setting but lymph nodes show viable metastatic carcinoma were also classified as MPR

Time frame: one month

pathological complete remission

proportion of patients without residual viable tumor cell on evaluation of resected lung cancer specimens including all sampled regional lymph nodes

Time frame: one month

survival time

time since diagnosed with NSCLC

Time frame: 5 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.